UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of EUR 924.64 million. The enterprise value is 926.82 million.

Market Cap	924.64M
Enterprise Value	926.82M

Important Dates

The next estimated earnings date is Friday, March 13, 2026.

Earnings Date	Mar 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.81M
Shares Outstanding	n/a
Shares Change (YoY)	+18.43%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	2.12%
Owned by Institutions (%)	80.51%
Float	37.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.24
PB Ratio	-9.40
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.60
EV / Sales	11.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.87

Financial Position

The company has a current ratio of 3.99

Current Ratio	3.99
Quick Ratio	3.47
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.94
Interest Coverage	-8.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-33.96%
Return on Invested Capital (ROIC)	-101.59%
Return on Capital Employed (ROCE)	-92.65%
Revenue Per Employee	286,622
Profits Per Employee	-488,935
Employee Count	235
Asset Turnover	0.40
Inventory Turnover	1.46

Taxes

In the past 12 months, UroGen Pharma has paid 2.56 million in taxes.

Income Tax	2.56M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+25.15%
50-Day Moving Average	17.90
200-Day Moving Average	14.06
Relative Strength Index (RSI)	49.36
Average Volume (20 Days)	10

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.62

Income Statement

In the last 12 months, UroGen Pharma had revenue of EUR 82.26 million and -140.32 million in losses. Loss per share was -2.95.

Revenue	82.26M
Gross Profit	72.35M
Operating Income	-112.76M
Pretax Income	-137.77M
Net Income	-140.32M
EBITDA	-111.74M
EBIT	-112.76M
Loss Per Share	-2.95

Full Income Statement

Balance Sheet

The company has 108.27 million in cash and 110.75 million in debt, giving a net cash position of -2.15 million.

Cash & Cash Equivalents	108.27M
Total Debt	110.75M
Net Cash	-2.15M
Net Cash Per Share	n/a
Equity (Book Value)	-98.36M
Book Value Per Share	-2.10
Working Capital	107.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -117.39 million and capital expenditures -329,840, giving a free cash flow of -117.72 million.

Operating Cash Flow	-117.39M
Capital Expenditures	-329,840
Free Cash Flow	-117.72M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 87.95%, with operating and profit margins of -137.08% and -170.59%.

Gross Margin	87.95%
Operating Margin	-137.08%
Pretax Margin	-167.47%
Profit Margin	-170.59%
EBITDA Margin	-135.84%
EBIT Margin	-137.08%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.43%
Shareholder Yield	-18.43%
Earnings Yield	-15.18%
FCF Yield	-12.73%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -6.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.96
Piotroski F-Score	2